Global Cholangiocarcinoma Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 185.4 Mn in 2021 and is expected to exhibit a CAGR of 12.8% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Rising research and development activities by pharmaceutical companies are expected to propel growth of the global cholangiocarcinoma market over the forecast period. For instance, in September 2019, Merck Sharp & Dohme Corp, a pharmaceutical company, initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment of cholangiocarcinoma. The study is currently in Phase 3 clinical trials and is expected to be completed by August 2023.
Global Cholangiocarcinoma Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has drastically affected the conductance clinical trials. Many trials have paused enrollment of participants and researchers are also facing multiple challenges associated with setting up remote visits and performing laboratory and other study assessments. According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software for clinical trials), on April 23, 2020, 63% of survey respondents reported that Pharmaceutical companies which were conducting clinical trials stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies. Even, the U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020, which were further updated on July 02, 2020. The guidelines included general considerations to assist sponsors and researchers, which ensures the safety of trial participants, and is in compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency.
Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Cholangiocarcinoma Market”- Forecast to 2028, Global Cholangiocarcinoma Market, By Treatment Type (Chemotherapy [Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU) ], Targeted Therapy, (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Moreover, increasing prevalence of cholangiocarcinoma is also expected to aid in growth of the Global Cholangiocarcinoma Market over the forecast period. For instance, according to World Cholangiocarcinoma Day Statistics in 2016, in May 2019, the incidence and mortality rates of cholangiocarcinoma in England were presented at the ESMO-GI2 conference in Barcelona, which showed that both incidence and mortality rates had been steadily increasing in England over the past 17 years (2001 – 2017). If this increase continues, then by 2030, cholangiocarcinoma will no longer be a rare cancer.
Key Takeaways of the Global Cholangiocarcinoma Market:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.